Apogee reports positive Phase 2 results for atopic dermatitis drug

May 27, 2026 6:30 AM

Apogee Therapeutics Inc. (NASDAQ: APGE) announced positive 16-week results from Part B of its Phase 2 APEX trial evaluating zumilokibart ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found